thought call
wed look past lilli mix result revenu ep bigger
pictur includ broadli differenti revenu non-gaap ep growth
recogn trough year dont envis portfolio risk
moder growth especi given strong demand trends/differenti
jardianc basaglar meaning revenu driver emgal
verzenio olumi begin contribut materi acknowledg
higher uncertainti tanezumab nevertheless multipl valu driver
near term add differenti growth narr includ rewind data
june data migrain market expans emgal label expans
lasmiditan approv addit olumi data atop dermat inde
suspect may see upsid lilli product cycl come month
trulicity/th class experi continu growth emgal secur
formulary/reimburs posit potenti outpac amgen aimovig
nbrx share quarter overal lilli remain one favorit name
pharma group base differenti growth vs peer enhanc oper leverag
full elanco spin complet strong new product cycl
inclus sever later-stag pipelin asset mirikizumab tirzepatid
maintain overweight rate lower pt
reflect modestli lower assumpt aftermath elanco spin-out
upcom pipelin catalyst watch recogn strong
run point sever event could drive upsid current level
rewind detail result june libretto data updat
phase cypress data nsclc phase cypress data nsclc
phase trial initi rcc late phase mirikizumab crohn
data ddw may phase tirzepatid dose escal data ada june
model chang given perform updat guidanc expect
revenu non-gaap ep estim move
given provid guidanc figur
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
multipl expans
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell barclay eli lilli co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
